JLK Signs Contract with Professor Nishita Singh's Team at University of Manitoba Hospital, 6th U.S. Base

JLKE has secured an additional foothold in North America and Canada by signing a comprehensive cooperation agreement with Dr. Nishita Singh's team at the University of Manitoba, marking its sixth partnership in the North American region.

On the 7th, JLKE, the first medical AI company to be listed, announced that its CEO, Dongmin Kim, successfully concluded a contract with Professor Nishita Singh's team at the University of Manitoba, a world-renowned expert in the field of stroke neurology.

Dr. Singh specializes in brain diseases including acute stroke and carotid artery disease-related strokes and has conducted numerous clinical trials in these areas. She is particularly knowledgeable about innovative treatment strategies for stroke and is involved in large-scale platform clinical trials and NIH (National Institutes of Health) funded studies, which are pioneering efforts in stroke research.

The University of Manitoba in Canada, where Dr. Singh is based, was established in 1877 as the first university in Western Canada and is recognized as a top research-intensive higher education institution. It has produced notable scholars including Nobel laureates, Academy Award winners, and recipients of the Order of Merit. Its medical school is especially known for significant achievements in research fields such as AIDS, cardiopulmonary function, and cancer biology.

Through this agreement, the company plans to continuously expand its base to Canada, a key market in North America. This is expected to establish a solid foundation in the North American medical market, which accounts for 42% of the global market, and facilitate the stable market entry of its AI solutions. Having already signed cooperation agreements with numerous faculty members, JLKE anticipates early achievement of its primary goal of comprehensive cooperation agreements with medical staff at 10 major base hospitals.

Dr. Singh, who has joined JLKE, stated, “I expect that this collaboration with JLKE will present a new paradigm in global stroke treatment guidelines,” adding, “I will focus on multinational clinical trials and other collaborations to support JLKE’s successful entry into the North American market as an AI medical company with a full-cycle stroke solution.”

JLKE CEO Dongmin Kim said, “It is deeply moving to see the rapid increase in multinational clinical research institutions for the stable initial entry of JLKE’s AI solutions,” and added, “We will do our best to expand base hospitals as promised this year to repay the support of our shareholders and to realize our North American market entry strategy without setbacks, striving for a swift market entry.”